FORA Capital LLC Makes New Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

FORA Capital LLC purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, HoldingsChannel reports. The firm purchased 10,226 shares of the company’s stock, valued at approximately $399,000.

Several other institutional investors have also made changes to their positions in MIRM. Candriam S.C.A. acquired a new stake in Mirum Pharmaceuticals during the second quarter worth about $17,384,000. Loomis Sayles & Co. L P bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $19,473,000. Clearbridge Investments LLC increased its stake in Mirum Pharmaceuticals by 165.5% in the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares during the last quarter. HealthInvest Partners AB raised its position in Mirum Pharmaceuticals by 83.9% during the third quarter. HealthInvest Partners AB now owns 138,321 shares of the company’s stock valued at $5,395,000 after purchasing an additional 63,121 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its stake in Mirum Pharmaceuticals by 791.7% during the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after purchasing an additional 51,482 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the sale, the senior vice president now owns 2,426 shares in the company, valued at $114,264.60. The trade was a 50.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $46.22 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -22.88 and a beta of 1.16. The company’s fifty day simple moving average is $40.93 and its 200 day simple moving average is $37.31. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same period in the previous year, the business earned ($0.57) EPS. The firm’s revenue was up 89.4% compared to the same quarter last year. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

MIRM has been the topic of several research analyst reports. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Evercore ISI boosted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Leerink Partners upped their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Buy” and an average price target of $57.73.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.